{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:36:10Z","timestamp":1679632570041},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00108-022-01443-4","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:04:58Z","timestamp":1671800698000},"page":"329-339","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Die Lunge: Ausgangspunkt vieler Erkrankungen"],"prefix":"10.1007","volume":"64","author":[{"given":"Rebecca","family":"Hasseli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Gall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3238\/arztebl.2016.0834","volume":"113","author":"D Berliner","year":"2016","unstructured":"Berliner\u00a0D, Schneider\u00a0N, Welte\u00a0T, Bauersachs\u00a0J (2016) The differential diagnosis of dyspnea. Dtsch Arztebl Int 113:834\u2013845. https:\/\/doi.org\/10.3238\/arztebl.2016.0834","journal-title":"Dtsch Arztebl Int"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMra020100","volume":"347","author":"J-F Bach","year":"2002","unstructured":"Bach\u00a0J\u2011F (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N\u00a0Engl J Med 347:911\u2013920. https:\/\/doi.org\/10.1056\/NEJMra020100","journal-title":"N Engl J Med"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton\u00a0CP, Khanna\u00a0D (2017) Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier\u00a0FM, Frommer\u00a0KW, Dinser\u00a0R, Walker\u00a0UA, Czirjak\u00a0L, Denton\u00a0CP et\u00a0al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355\u20131360. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200742","journal-title":"Ann Rheum Dis"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/ard.2008.106302","volume":"68","author":"M Matucci-Cerinic","year":"2009","unstructured":"Matucci-Cerinic\u00a0M, Allanore\u00a0Y, Czirjak\u00a0L, Tyndall\u00a0A, Muller-Ladner\u00a0U, Denton\u00a0C et al (2009) The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a\u00a0prevention or rescue strategy. Ann Rheum Dis 68:1377\u20131380. https:\/\/doi.org\/10.1136\/ard.2008.106302","journal-title":"Ann Rheum Dis"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai\u00a0M, Meune\u00a0C, Avouac\u00a0J, Kahan\u00a0A, Allanore\u00a0Y (2012) Trends in mortality in patients with systemic sclerosis over 40\u00a0years: a\u00a0systematic review and meta-analysis of cohort studies. Baillieres Clin Rheumatol 51:1017\u20131026. https:\/\/doi.org\/10.1093\/rheumatology\/ker269","journal-title":"Baillieres Clin Rheumatol"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00393-022-01200-w","volume":"81","author":"R Hasseli-Frabel","year":"2022","unstructured":"Hasseli-Frabel\u00a0R, Hermann\u00a0W, Sander\u00a0O, Triantafyllias\u00a0K (2022) Nailfold capillaroscopy-principles and clinical application. Z\u00a0Rheumatol 81:313\u2013322. https:\/\/doi.org\/10.1007\/s00393-022-01200-w","journal-title":"Z Rheumatol"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore\u00a0Y, Simms\u00a0R, Distler\u00a0O, Trojanowska\u00a0M, Pope\u00a0J, Denton\u00a0CP, Varga\u00a0J (2015) Systemic sclerosis. Nat Rev Dis Primers 1:15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Primers"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/BOR.0000000000000331","volume":"28","author":"RG Marangoni","year":"2016","unstructured":"Marangoni\u00a0RG, Varga\u00a0J, Tourtellotte\u00a0WG (2016) Animal models of scleroderma: recent progress. Curr Opin Rheumatol 28:561\u2013570. https:\/\/doi.org\/10.1097\/BOR.0000000000000331","journal-title":"Curr Opin Rheumatol"},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen\u00a0F, Khanna\u00a0D, Fransen\u00a0J, Johnson\u00a0SR, Baron\u00a0M, Tyndall\u00a0A et\u00a0al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall\u00a0AJ, Bannert\u00a0B, Vonk\u00a0M, Airo\u00a0P, Cozzi\u00a0F, Carreira\u00a0PE et\u00a0al (2010) Causes and risk factors for death in systemic sclerosis: a\u00a0study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264","journal-title":"Ann Rheum Dis"},{"key":"1443_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna\u00a0D, Furst\u00a0DE, Clements\u00a0PJ, Allanore\u00a0Y, Baron\u00a0M, Czirjak\u00a0L et\u00a0al (2017) Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J\u00a0Scleroderma Relat Disord 2:11\u201318. https:\/\/doi.org\/10.5301\/jsrd.5000231","journal-title":"J Scleroderma Relat Disord"},{"key":"1443_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J, Becker\u00a0M, Kulak\u00a0A, Allanore\u00a0Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"1443_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","volume":"50","author":"M Bassel","year":"2011","unstructured":"Bassel\u00a0M, Hudson\u00a0M, Taillefer\u00a0SS, Schieir\u00a0O, Baron\u00a0M, Thombs\u00a0BD (2011) Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a\u00a0Canadian National Survey. Rheumatology 50:762\u2013767. https:\/\/doi.org\/10.1093\/rheumatology\/keq310","journal-title":"Rheumatology"},{"key":"1443_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","author":"M Humbert","year":"2022","unstructured":"Humbert\u00a0M, Kovacs\u00a0G, Hoeper\u00a0MM, Badagliacca\u00a0R, Berger\u00a0RMF, Brida\u00a0M et\u00a0al (2022) 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"key":"1443_CR16","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.100245","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac\u00a0J, Airo\u00a0P, Meune\u00a0C, Beretta\u00a0L, Dieude\u00a0P, Caramaschi\u00a0P et\u00a0al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5\u00a0studies. J\u00a0Rheumatol 37:2290\u20132298. https:\/\/doi.org\/10.3899\/jrheum.100245","journal-title":"J Rheumatol"},{"key":"1443_CR17","doi-asserted-by":"publisher","first-page":"e12118","DOI":"10.1002\/pul2.12118","volume":"12","author":"K Alman","year":"2022","unstructured":"Alman\u00a0K, Sadd\u00a0CJ, Ravel\u00a0A, Raza\u00a0F, Chybowski\u00a0A, Runo\u00a0JR (2022) Prevalence of aortic stenosis and TAVR outcomes in patients with systemic sclerosis-associated pulmonary hypertension. Pulm Circ 12:e12118. https:\/\/doi.org\/10.1002\/pul2.12118","journal-title":"Pulm Circ"},{"key":"1443_CR18","doi-asserted-by":"publisher","first-page":"e12127","DOI":"10.1002\/pul2.12127","volume":"12","author":"SM Nikkho","year":"2022","unstructured":"Nikkho\u00a0SM, Richter\u00a0MJ, Shen\u00a0E, Abman\u00a0SH, Antoniou\u00a0K, Chung\u00a0J et al (2022) Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute\u2019s innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ 12:e12127. https:\/\/doi.org\/10.1002\/pul2.12127","journal-title":"Pulm Circ"},{"key":"1443_CR19","doi-asserted-by":"publisher","first-page":"e12060","DOI":"10.1002\/pul2.12060","volume":"12","author":"I Mitrouska","year":"2022","unstructured":"Mitrouska\u00a0I, Bolaki\u00a0M, Vaporidi\u00a0K, Georgopoulos\u00a0D (2022) Respiratory system as the main determinant of dyspnea in patients with pulmonary hypertension. Pulm circ 12:e12060. https:\/\/doi.org\/10.1002\/pul2.12060","journal-title":"Pulm circ"},{"key":"1443_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie\u00a0N, Humbert\u00a0M, Vachiery\u00a0JL, Gibbs\u00a0S, Lang\u00a0I, Torbicki\u00a0A et\u00a0al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart\u00a0J 37:67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317","journal-title":"Eur Heart J"},{"key":"1443_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7.","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ, Furst\u00a0DE, Khanna\u00a0D, Kleerup\u00a0EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"1443_CR22","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin\u00a0DP, Elashoff\u00a0R, Clements\u00a0PJ, Goldin\u00a0J, Roth\u00a0MD, Furst\u00a0DE et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"1443_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04538-2020","author":"KR Flaherty","year":"2022","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V, Devaraj\u00a0A, Inoue\u00a0Y, Richeldi\u00a0L et\u00a0al (2022) Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.04538-2020","journal-title":"Eur Respir J"},{"key":"1443_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1.","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland\u00a0KB, Distler\u00a0O, Kuwana\u00a0M, Allanore\u00a0Y, Assassi\u00a0S, Azuma\u00a0A et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a\u00a0subgroup analysis of the SENSCIS trial. Lancet Respir Med 9:96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"key":"1443_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/a-1658-5176","volume":"147","author":"M Aringer","year":"2022","unstructured":"Aringer\u00a0M, Koschel\u00a0D, Krause\u00a0A, Schneider\u00a0U, Glaser\u00a0S (2022) Modern drug therapy for systemic sclerosis associated interstitial lung disease. Dtsch Med Wochenschr 147:179\u2013186. https:\/\/doi.org\/10.1055\/a-1658-5176","journal-title":"Dtsch Med Wochenschr"},{"key":"1443_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","volume":"361","author":"RP Baughman","year":"2003","unstructured":"Baughman\u00a0RP, Lower\u00a0EE, Du Bois\u00a0RM (2003) Sarcoidosis. Lancet 361:1111\u20131118. https:\/\/doi.org\/10.1016\/S0140-6736(03)12888-7","journal-title":"Lancet"},{"key":"1443_CR27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7.","volume":"383","author":"D Valeyre","year":"2014","unstructured":"Valeyre\u00a0D, Prasse\u00a0A, Nunes\u00a0H, Uzunhan\u00a0Y, Brillet\u00a0PY, Muller-Quernheim\u00a0J (2014) Sarcoidosis. Lancet 383:1155\u20131167. https:\/\/doi.org\/10.1016\/S0140-6736(13)60680-7","journal-title":"Lancet"},{"key":"1443_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3389\/fimmu.2020.00474","volume":"11","author":"SA Greaves","year":"2020","unstructured":"Greaves\u00a0SA, Atif\u00a0SM, Fontenot\u00a0AP (2020) Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease. Front Immunol 11:474. https:\/\/doi.org\/10.3389\/fimmu.2020.00474","journal-title":"Front Immunol"},{"key":"1443_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","volume":"76","author":"M Thillai","year":"2021","unstructured":"Thillai\u00a0M, Atkins\u00a0CP, Crawshaw\u00a0A, Hart\u00a0SP, Ho\u00a0LP, Kouranos\u00a0V et\u00a0al (2021) BTS clinical statement on pulmonary sarcoidosis. Thorax 76:4\u201320. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214348","journal-title":"Thorax"},{"key":"1443_CR30","doi-asserted-by":"publisher","first-page":"204589401988262","DOI":"10.1177\/2045894019882620","volume":"10","author":"S Narechania","year":"2020","unstructured":"Narechania\u00a0S, Renapurkar\u00a0R, Heresi\u00a0GA (2020) Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a\u00a0review. Pulm circ 10:2045894019882620. https:\/\/doi.org\/10.1177\/2045894019882620","journal-title":"Pulm circ"},{"key":"1443_CR31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.rmed.2011.08.012","volume":"105","author":"RL Mostard","year":"2011","unstructured":"Mostard\u00a0RL, Voo\u00a0S, van Kroonenburgh\u00a0MJ, Verschakelen\u00a0JA, Wijnen\u00a0PA, Nelemans\u00a0PJ et al (2011) Inflammatory activity assessment by F18 FDG-PET\/CT in persistent symptomatic sarcoidosis. Respir Med 105:1917\u20131924. https:\/\/doi.org\/10.1016\/j.rmed.2011.08.012","journal-title":"Respir Med"},{"key":"1443_CR32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","author":"RP Baughman","year":"2021","unstructured":"Baughman\u00a0RP, Valeyre\u00a0D, Korsten\u00a0P, Mathioudakis\u00a0AG, Wuyts\u00a0WA, Wells\u00a0A et\u00a0al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.04079-2020","journal-title":"Eur Respir J"},{"key":"1443_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1.","volume":"398","author":"JF Emile","year":"2021","unstructured":"Emile\u00a0JF, Cohen-Aubart\u00a0F, Collin\u00a0M, Fraitag\u00a0S, Idbaih\u00a0A, Abdel-Wahab\u00a0O et al (2021) Histiocytosis. Lancet 398:157\u2013170. https:\/\/doi.org\/10.1016\/S0140-6736(21)00311-1","journal-title":"Lancet"},{"key":"1443_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MCP.0000000000000470","volume":"24","author":"NA Brown","year":"2018","unstructured":"Brown\u00a0NA, Elenitoba-Johnson\u00a0KSJ (2018) Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis. Curr Opin Pulm Med 24:281\u2013286. https:\/\/doi.org\/10.1097\/MCP.0000000000000470","journal-title":"Curr Opin Pulm Med"},{"key":"1443_CR35","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/ajh.26355","volume":"96","author":"AZ Hazim","year":"2021","unstructured":"Hazim\u00a0AZ, Ruan\u00a0GJ, Hu\u00a0M, Ravindran\u00a0A, Rech\u00a0KL, Young\u00a0JR et\u00a0al (2021) Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. Am J Hematol 96:1604\u20131610. https:\/\/doi.org\/10.1002\/ajh.26355","journal-title":"Am J Hematol"},{"key":"1443_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejim.2015.04.001","volume":"26","author":"D Elia","year":"2015","unstructured":"Elia\u00a0D, Torre\u00a0O, Cassandro\u00a0R, Caminati\u00a0A, Harari\u00a0S (2015) Pulmonary Langerhans cell histiocytosis: a\u00a0comprehensive analysis of 40\u00a0patients and literature review. Eur J Intern Med 26:351\u2013356. https:\/\/doi.org\/10.1016\/j.ejim.2015.04.001","journal-title":"Eur J Intern Med"},{"key":"1443_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/a-1120-3531","volume":"74","author":"J Behr","year":"2020","unstructured":"Behr\u00a0J, G\u00fcnther\u00a0A, Bonella\u00a0F, Dinkel\u00a0J, Fink\u00a0L, Geiser\u00a0T et al (2020) S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose. [German Guideline for Idiopathic Pulmonary Fibrosis]. Pneumologie 74:263\u2013293. https:\/\/doi.org\/10.1055\/a-1120-3531","journal-title":"Pneumologie"},{"key":"1443_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1055\/s-0043-106160","volume":"71","author":"J Behr","year":"2017","unstructured":"Behr\u00a0J, G\u00fcnther\u00a0A, Bonella\u00a0F, Gei\u00dfler\u00a0K, Koschel\u00a0D, Kreuter\u00a0M et al (2017) S2k-Leitlinie Idiopathische Lungenfibrose\u2014Update zur medikament\u00f6sen Therapie 2017. [German Guideline for Idiopathic Pulmonary Fibrosis\u2014Update on Pharmacological Therapies 2017. Pneumologie 71:460\u2013474. https:\/\/doi.org\/10.1055\/s-0043-106160","journal-title":"Pneumologie"},{"key":"1443_CR39","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0018","author":"M Kreuter","year":"2021","unstructured":"Kreuter\u00a0M, Ladner\u00a0UM, Costabel\u00a0U, Jonigk\u00a0D, Heussel\u00a0CP (2021) The diagnosis and treatment of pulmonary fibrosis. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2021.0018","journal-title":"Dtsch Arztebl Int"},{"key":"1443_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10405-021-00402-4","volume":"18","author":"C Dodt","year":"2021","unstructured":"Dodt\u00a0C, Pletz\u00a0MW, Kolditz\u00a0M (2021) Pr\u00e4vention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und \u201ecoronavirus disease 2019\u201c. [Prevention by vaccination of adult patients with pulmonary diseases]. Pneumologe 18:327\u2013338. https:\/\/doi.org\/10.1007\/s10405-021-00402-4","journal-title":"Pneumologe"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01443-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T12:03:45Z","timestamp":1679573025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01443-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"7 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Hasseli, H.\u00a0Gall und M.J.\u00a0Richter geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}